Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 9
2004 14
2005 2
2006 14
2007 9
2008 10
2009 3
2010 1
2011 1
2012 2
2013 3
2014 2
2015 3
2016 4
2018 1
2019 1
2020 5
2021 6
2022 4
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Kimura T, et al. Among authors: kageyama y. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013. Epub 2023 May 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 37196834 Free article. Clinical Trial.
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. Yoshida S, et al. Among authors: kageyama y. BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z. BMC Urol. 2023. PMID: 36879257 Free PMC article. Clinical Trial.
Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Kijima T, et al. Among authors: kageyama y. Clin Genitourin Cancer. 2021 Jun;19(3):208-216.e1. doi: 10.1016/j.clgc.2020.07.003. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32800718 Review.
Dedifferentiated solitary fibrous tumor of the kidney: A case report.
Izumi K, Inoue M, Maruyama R, Ishikawa A, Kanda H, Kageyama Y. Izumi K, et al. Among authors: kageyama y. Urol Case Rep. 2022 May 1;43:102100. doi: 10.1016/j.eucr.2022.102100. eCollection 2022 Jul. Urol Case Rep. 2022. PMID: 35573086 Free PMC article.
Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.
Kurashina R, Ando K, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y. Kurashina R, et al. Among authors: kageyama y. Cancer Diagn Progn. 2023 Mar 3;3(2):230-235. doi: 10.21873/cdp.10206. eCollection 2023 Mar-Apr. Cancer Diagn Progn. 2023. PMID: 36875313 Free PMC article.
106 results